首页 > 最新文献

Clinical and Translational Allergy最新文献

英文 中文
Proof-of-concept study of anti-Fel d 1 IgY antibodies in cat food using the MASK-air® app 使用 MASK-air® 应用程序对猫粮中抗 Fel d 1 IgY 抗体进行概念验证研究
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2024-04-27 DOI: 10.1002/clt2.12353
Jean Bousquet, Alina Gherasim, Frédéric de Blay, Eve Mathieu-Dupas, Géraldine Batot, Daniel Laune, Bernardo Sousa-Pinto, Torsten Zuberbier, Nhân Pham-Thi, MASK-cat study group

Background

An innovation to better manage cat-allergic patients utilises anti-Fel d 1 IgY antibodies to neutralise Fel d 1 after its production by the cat. However, there is no published study showing its clinical efficacy in humans in a home setting. A longitudinal, open-label, proof-of-concept study was carried out to approach clinical efficacy of the cat food in cat-allergic patients.

Methods

After a baseline evaluation, the cats ate only the cat food for the following 4 months. Daily evaluation of efficacy was performed for 2 weeks at baseline and after 1, 2 and 3 months of intervention for periods of 2 weeks. The MASK-air app was used daily to assess symptoms, work productivity and medications.

Results

Of the 49 patients screened, 42 were followed up and 33 (78.5%) reported MASK-air data at all 3 evaluation periods. The primary end point (visual analogue scale [VAS] for global allergy symptoms) was significantly improved (p < 0.0001). All symptoms (VAS nose, eye, and asthma), VAS work and the combined symptom-medication score significantly improved after 1 month. The percentage of uncontrolled days (VAS>20/100) decreased from 64% at baseline to 35% at 1 month (p < 0.0001) and 14% at 3 months. A sensitivity analysis in patients with uncontrolled disease at baseline found similar results.

Discussion

A cat diet containing anti-Fel d 1 antibodies was able to (i) show decreased allergic symptoms and related outcomes, (ii) inform the design and feasibility of future studies with a control arm and (iii) estimate the sample size of the study.

Study registration number: clinicaltrials.gov: NCT05656482.

背景 为更好地管理对猫过敏的病人,一种创新方法是利用抗 Fel d 1 IgY 抗体来中和猫体内产生的 Fel d 1。然而,目前还没有公开发表的研究结果表明其在家庭环境中对人类的临床疗效。我们开展了一项纵向、开放标签、概念验证研究,以接近该猫粮对猫过敏患者的临床疗效。 方法 在进行基线评估后,猫咪在随后的 4 个月中只食用猫粮。在基线期和干预 1、2 和 3 个月后的 2 周内,每天对疗效进行评估。每天使用 MASK-air 应用程序评估症状、工作效率和用药情况。 结果 在接受筛查的 49 名患者中,42 人接受了随访,33 人(78.5%)在所有 3 个评估期间都报告了 MASK-air 数据。主要终点(全面过敏症状的视觉模拟量表[VAS])明显改善(p < 0.0001)。1 个月后,所有症状(VAS 鼻、眼和哮喘)、VAS 工作和症状-用药综合评分均有明显改善。不受控制的天数百分比(VAS>20/100)从基线时的 64% 降至 1 个月时的 35%(p <0.0001)和 3 个月时的 14%。对基线病情未得到控制的患者进行的敏感性分析也发现了类似的结果。 讨论 含有抗 Fel d 1 抗体的猫粮能够(i)减少过敏症状和相关结果,(ii)为未来带有对照组的研究的设计和可行性提供信息,(iii)估计研究的样本量。 研究注册号:clinicaltrials.gov:NCT05656482。
{"title":"Proof-of-concept study of anti-Fel d 1 IgY antibodies in cat food using the MASK-air® app","authors":"Jean Bousquet,&nbsp;Alina Gherasim,&nbsp;Frédéric de Blay,&nbsp;Eve Mathieu-Dupas,&nbsp;Géraldine Batot,&nbsp;Daniel Laune,&nbsp;Bernardo Sousa-Pinto,&nbsp;Torsten Zuberbier,&nbsp;Nhân Pham-Thi,&nbsp;MASK-cat study group","doi":"10.1002/clt2.12353","DOIUrl":"https://doi.org/10.1002/clt2.12353","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>An innovation to better manage cat-allergic patients utilises anti-Fel d 1 IgY antibodies to neutralise Fel d 1 after its production by the cat. However, there is no published study showing its clinical efficacy in humans in a home setting. A longitudinal, open-label, proof-of-concept study was carried out to approach clinical efficacy of the cat food in cat-allergic patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>After a baseline evaluation, the cats ate only the cat food for the following 4 months. Daily evaluation of efficacy was performed for 2 weeks at baseline and after 1, 2 and 3 months of intervention for periods of 2 weeks. The MASK-air app was used daily to assess symptoms, work productivity and medications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 49 patients screened, 42 were followed up and 33 (78.5%) reported MASK-air data at all 3 evaluation periods. The primary end point (visual analogue scale [VAS] for global allergy symptoms) was significantly improved (<i>p</i> &lt; 0.0001). All symptoms (VAS nose, eye, and asthma), VAS work and the combined symptom-medication score significantly improved after 1 month. The percentage of uncontrolled days (VAS&gt;20/100) decreased from 64% at baseline to 35% at 1 month (<i>p</i> &lt; 0.0001) and 14% at 3 months. A sensitivity analysis in patients with uncontrolled disease at baseline found similar results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>A cat diet containing anti-Fel d 1 antibodies was able to (i) show decreased allergic symptoms and related outcomes, (ii) inform the design and feasibility of future studies with a control arm and (iii) estimate the sample size of the study.</p>\u0000 \u0000 <p><b>Study registration number</b>: clinicaltrials.gov: <b>NCT05656482</b>.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12353","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140649553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comorbidities of chronic rhinosinusitis in children and adults 儿童和成人慢性鼻炎的并发症
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2024-04-24 DOI: 10.1002/clt2.12354
Aada Murtomäki, Alma Helevä, Paulus Torkki, Jari Haukka, Anna Julkunen-Iivari, Riikka Lemmetyinen, Mika Mäkelä, Aarno Dietz, Mikko Nuutinen, Sanna Toppila-Salmi

Background

Chronic rhinosinusitis (CRS) is a chronic inflammatory disease of the nose and paranasal sinuses lasting ≥12 weeks. CRS may exist with (CRSwNP) or without (CRSsNP) nasal polyps. The aim was to evaluate conditions associated with CRS in a randomized hospital cohort. We hypothesized that comorbidities and surgical procedures differ between pediatric and adult patients.

Methods

This study consisted of hospital registry data of a random sample of rhinosinusitis patients (age range 0–89 years) with the diagnosis of J32 or J33, correspondingly, registered during outpatient visits from 2005 to 2019 (n = 1461). The covariates of interest were collected from electronic health records based on ICD-10 codes and keyword searches.

Results

Among pediatric patients (n = 104), the relative proportions of CRSsNP and CRSwNP were 86% and 14% respectively. The relative proportions of adult patients (n = 1357) with CRSsNP and CRSwNP were 60% and 40%, respectively. The following comorbidities significantly differed (p < 0.05) between pediatric and adult populations: allergy, chronic otitis media, and tonsillar diseases. In total, 41 % of the children and 46% of the adults underwent baseline endoscopic sinus surgery (ESS). Additional surgeries of the ear, nose and pharynx were significantly more common among children compared with adults. Risk of revision after baseline ESS was associated (p < 0.05) with allergy, asthma, eosinophilia, CRSwNP, immunodeficiency or its suspicion, non-steroidal anti-inflammatory drug exacerbated respiratory disease, and number of any diseases ≥2.

Conclusions

Our study showed that comorbidities differ between pediatric and adult rhinosinusitis patients, as allergy, asthma and allergy, chronic otitis media, mental health disorders, and tonsils disease were significantly more prevalent among pediatric patients. Children and adults were equally treated with ESS. Notably, children underwent additional surgery on adenoids and tonsils more frequently. The effectiveness of ESS in multimorbid adults should be assessed at an individual level.

背景 慢性鼻窦炎(CRS)是鼻腔和副鼻窦的一种慢性炎症性疾病,病程≥12 周。CRS可能伴有鼻息肉(CRSwNP),也可能不伴有鼻息肉(CRSsNP)。我们的目的是在随机医院队列中评估与 CRS 相关的情况。我们假设儿童患者和成人患者的合并症和手术程序有所不同。 方法 本研究包括 2005 年至 2019 年期间门诊登记的随机样本鼻窦炎患者(年龄在 0-89 岁之间)的医院登记数据,诊断结果相应为 J32 或 J33(n = 1461)。相关协变量是根据 ICD-10 编码和关键词搜索从电子病历中收集的。 结果 在儿科患者(n = 104)中,CRSsNP 和 CRSwNP 的相对比例分别为 86% 和 14%。成人患者(n = 1357)中,CRSsNP 和 CRSwNP 的相对比例分别为 60% 和 40%。以下合并症在儿童和成人之间存在显著差异(p < 0.05):过敏、慢性中耳炎和扁桃体疾病。共有 41% 的儿童和 46% 的成人接受了基线内窥镜鼻窦手术(ESS)。与成人相比,儿童接受耳鼻喉和咽部额外手术的比例明显更高。基线ESS术后复查的风险与过敏、哮喘、嗜酸性粒细胞增多症、CRSwNP、免疫缺陷或疑似免疫缺陷、非甾体类抗炎药加重的呼吸道疾病以及任何疾病的数量≥2有关(p < 0.05)。 结论 我们的研究表明,儿童鼻炎患者和成人鼻炎患者的合并症有所不同,因为过敏、哮喘和过敏、慢性中耳炎、精神疾病和扁桃体疾病在儿童患者中的发病率明显更高。儿童和成人接受 ESS 治疗的情况相同。值得注意的是,儿童接受腺样体和扁桃体额外手术的频率更高。ESS对多病成人的疗效应根据个体情况进行评估。
{"title":"Comorbidities of chronic rhinosinusitis in children and adults","authors":"Aada Murtomäki,&nbsp;Alma Helevä,&nbsp;Paulus Torkki,&nbsp;Jari Haukka,&nbsp;Anna Julkunen-Iivari,&nbsp;Riikka Lemmetyinen,&nbsp;Mika Mäkelä,&nbsp;Aarno Dietz,&nbsp;Mikko Nuutinen,&nbsp;Sanna Toppila-Salmi","doi":"10.1002/clt2.12354","DOIUrl":"https://doi.org/10.1002/clt2.12354","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic rhinosinusitis (CRS) is a chronic inflammatory disease of the nose and paranasal sinuses lasting ≥12 weeks. CRS may exist with (CRSwNP) or without (CRSsNP) nasal polyps. The aim was to evaluate conditions associated with CRS in a randomized hospital cohort. We hypothesized that comorbidities and surgical procedures differ between pediatric and adult patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study consisted of hospital registry data of a random sample of rhinosinusitis patients (age range 0–89 years) with the diagnosis of J32 or J33, correspondingly, registered during outpatient visits from 2005 to 2019 (<i>n</i> = 1461). The covariates of interest were collected from electronic health records based on ICD-10 codes and keyword searches.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among pediatric patients (<i>n</i> = 104), the relative proportions of CRSsNP and CRSwNP were 86% and 14% respectively. The relative proportions of adult patients (<i>n</i> = 1357) with CRSsNP and CRSwNP were 60% and 40%, respectively. The following comorbidities significantly differed (<i>p</i> &lt; 0.05) between pediatric and adult populations: allergy, chronic otitis media, and tonsillar diseases. In total, 41 % of the children and 46% of the adults underwent baseline endoscopic sinus surgery (ESS). Additional surgeries of the ear, nose and pharynx were significantly more common among children compared with adults. Risk of revision after baseline ESS was associated (<i>p</i> &lt; 0.05) with allergy, asthma, eosinophilia, CRSwNP, immunodeficiency or its suspicion, non-steroidal anti-inflammatory drug exacerbated respiratory disease, and number of any diseases ≥2.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study showed that comorbidities differ between pediatric and adult rhinosinusitis patients, as allergy, asthma and allergy, chronic otitis media, mental health disorders, and tonsils disease were significantly more prevalent among pediatric patients. Children and adults were equally treated with ESS. Notably, children underwent additional surgery on adenoids and tonsils more frequently. The effectiveness of ESS in multimorbid adults should be assessed at an individual level.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12354","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140641853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consumption of cow's milk formula in the nursery and the development of milk allergy 在婴儿期食用牛奶配方奶粉与牛奶过敏症的发生
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2024-04-12 DOI: 10.1002/clt2.12352
Arnon Elizur, Shirel Rachel-Jossefi, Marianna Rachmiel, Eli Eisenberg, Yitzhak Katz

Background

The effect of the amount of transient cow's milk formula (CMF) consumed during the first days of life on IgE-cow's milk allergy (IgE-CMA) is unknown.

Methods

A cohort of 58 patients with IgE-CMA was identified from a large scale population-based study of 13,019 infants followed from birth. A group of 116 infants matched for sex and breastfeeding only duration (beyond the nursery period), and another random group of 259 healthy infants were used as controls. Parents were interviewed and the infants' medical records were searched to assess CMF consumption in the nursery.

Results

While 96% of the mothers of the 174 infants (58 with Cow's milk allergy and 116 controls) reported on exclusive breastfeeding during the stay in the nursery, CMF consumption was documented in 96 (55%) of the infants. Of those, most (57; 59%) received one to three feedings, 20 (21%) received four to nine feedings, and 19 (20%) received ≥10 feedings. Fewer formula feeds (1–3) were significantly more common in the allergic group than ≥4 feeds (p = 0.0003) and no feeds at all (p = 0.02) compared to controls (n = 116). Of those exclusively breastfed in the nursery, 13/23 allergic infants (57%) introduced CMF at age 105–194 days (the period with highest-risk for IgE-CMA) compared to 33/98 (34%) from the random control group (n = 259) (p = 0.04).

Conclusions

Most infants end up receiving few CMF feeds in the nursery. Transient CMF in the nursery is associated with increased risk of IgE-CMA.

背景 出生后最初几天食用的短暂牛乳配方奶(CMF)量对 IgE-牛乳过敏(IgE-CMA)的影响尚不清楚。 方法 在对 13,019 名婴儿进行的大规模人群研究中,发现了 58 名 IgE-CMA 患者。一组是性别和母乳喂养时间(超过育婴期)相匹配的 116 名婴儿,另一组是随机抽取的 259 名健康婴儿,作为对照组。研究人员对父母进行了访谈,并对婴儿的医疗记录进行了检索,以评估婴儿在育婴期间的 CMF 消费情况。 结果 在 174 名婴儿(58 名牛乳过敏婴儿和 116 名对照组婴儿)的母亲中,96% 的母亲表示在婴儿保育院期间进行了纯母乳喂养,96 名婴儿(55%)食用了 CMF。其中,大多数婴儿(57;59%)喂食一至三次,20(21%)喂食四至九次,19(20%)喂食≥十次。与对照组(n = 116)相比,过敏组配方奶喂养次数较少(1-3 次)的情况明显多于喂养次数≥4 次(p = 0.0003)和完全不喂养(p = 0.02)的情况。在育婴室纯母乳喂养的婴儿中,有 13/23 名过敏婴儿(57%)在 105-194 天时(IgE-CMA 风险最高的时期)添加了 CMF,而随机对照组(n = 259)中有 33/98 名婴儿(34%)添加了 CMF(p = 0.04)。 结论 大多数婴儿最终在保育室接受的 CMF 喂养很少。育婴室中短暂的 CMF 与 IgE-CMA 风险增加有关。
{"title":"Consumption of cow's milk formula in the nursery and the development of milk allergy","authors":"Arnon Elizur,&nbsp;Shirel Rachel-Jossefi,&nbsp;Marianna Rachmiel,&nbsp;Eli Eisenberg,&nbsp;Yitzhak Katz","doi":"10.1002/clt2.12352","DOIUrl":"https://doi.org/10.1002/clt2.12352","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The effect of the amount of transient cow's milk formula (CMF) consumed during the first days of life on IgE-cow's milk allergy (IgE-CMA) is unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cohort of 58 patients with IgE-CMA was identified from a large scale population-based study of 13,019 infants followed from birth. A group of 116 infants matched for sex and breastfeeding only duration (beyond the nursery period), and another random group of 259 healthy infants were used as controls. Parents were interviewed and the infants' medical records were searched to assess CMF consumption in the nursery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>While 96% of the mothers of the 174 infants (58 with Cow's milk allergy and 116 controls) reported on exclusive breastfeeding during the stay in the nursery, CMF consumption was documented in 96 (55%) of the infants. Of those, most (57; 59%) received one to three feedings, 20 (21%) received four to nine feedings, and 19 (20%) received ≥10 feedings. Fewer formula feeds (1–3) were significantly more common in the allergic group than ≥4 feeds (<i>p</i> = 0.0003) and no feeds at all (<i>p</i> = 0.02) compared to controls (<i>n</i> = 116). Of those exclusively breastfed in the nursery, 13/23 allergic infants (57%) introduced CMF at age 105–194 days (the period with highest-risk for IgE-CMA) compared to 33/98 (34%) from the random control group (<i>n</i> = 259) (<i>p</i> = 0.04).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Most infants end up receiving few CMF feeds in the nursery. Transient CMF in the nursery is associated with increased risk of IgE-CMA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12352","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140550043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dilemmas of nomenclature: Web search analysis reveals European preferences in atopic skin diseases 术语难题:网络搜索分析揭示欧洲对特应性皮肤病的偏好
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2024-04-12 DOI: 10.1002/clt2.12355
Hannah Wecker, Stefanie Ziehfreund, Sebastian Sitaru, Emma K. Johansson, Jesper Elberling, Anaïs Doll, Electra Nicolaidou, Emanuele Scala, Michael J. Boffa, Lea Schmidt, Mariusz Sikora, Tiago Torres, Pavel V. Chernyshov, Alexander Zink
<p>Atopic dermatitis (AD) or atopic eczema (AE) is a complex chronic inflammatory skin disease with a high prevalence and disease burden.<span><sup>1</sup></span> The nomenclature for this condition has long been the subject of controversial debate within the medical community and even among global experts.<span><sup>2, 3</sup></span> However, the terminology used not only affects experts, daily clinical practice, and research but especially patients and the general public in terms of their understanding and access to disease-related information.<span><sup>2-5</sup></span> Given the potential of crowdsourced internet data,<span><sup>6</sup></span> this study aimed to investigate the use of ‘atopic dermatitis’, ‘atopic eczema’, and their lay terms in internet searches and the content of these searches across 21 European countries in their respective main language.</p><p>A total of 71,620,240 AD-related searches, 33,913,480 AE-related searches, and 136,405,350 searches to the respective lay terms were identified across European countries between 02/2019 and 01/2023 using Google Ads Keyword Planner. The top 20 keywords for each country and search term were translated into English and inductively classified into 9 categories: <i>age group</i>, <i>causes</i>, <i>comorbidities</i>, <i>general</i> information, <i>localisation</i>, <i>other disease</i>, <i>others</i>, <i>symptoms</i>, and <i>treatment</i>. Subcategories were formed for recurring keywords, for example, different body localisations. For cross-country comparison, the monthly number of web searches per 100,000 inhabitants was calculated. For detailed methodology, see the Appendix.</p><p>Most European countries (<i>n</i> = 11) had the highest median number of web searches per 100,000 inhabitants for AD-related lay terms, followed by AD (<i>n</i> = 8) and AE (<i>n</i> = 2, Figure 1). Analysis revealed common search themes across European countries, including <i>general</i> disease information, <i>age groups</i>, <i>localisations</i>, and <i>treatment</i>, with slight variations between countries (Figure 2A). The lay term's keywords were often about other diseases. Depending on the search terms, internet queries in some categories focused on different subcategories (Figure 2B). For example, when using the lay term, more countries searched for <i>(natural) remedies</i> and anogenital localisations, and only AD-related searches included searches for <i>animals</i>. However, there were also similarities between the search terms, with <i>face</i>, <i>hands</i>, and <i>scalp</i> being the most frequently searched localisations. <i>Age-</i>related internet searches concerned primarily babies and children, whereas in Austria and Germany, adults were the only search subjects. Search content for lay terms appeared less differentiated than for the other search terms.</p><p>Consistent with previous research, both a review study and a global crowdsourced approach found that the term AD was used more freque
特应性皮炎(AD)或特应性湿疹(AE)是一种复杂的慢性炎症性皮肤病,发病率和疾病负担都很高。1 长期以来,医学界甚至全球专家对这种疾病的术语一直存在争议。鉴于众包互联网数据6 的潜力,本研究旨在调查 "特应性皮炎"、"特应性湿疹 "及其非专业术语在互联网搜索中的使用情况,以及这些搜索在 21 个欧洲国家各自主要语言中的内容。每个国家和搜索词的前 20 个关键词被翻译成英文,并归纳为 9 个类别:年龄组、病因、合并症、一般信息、定位、其他疾病、其他、症状和治疗。对于重复出现的关键词,例如不同的身体定位,则会形成子类别。为了进行跨国比较,我们计算了每 10 万居民每月的网络搜索次数。大多数欧洲国家(n = 11)每 100,000 名居民中与 AD 相关的非专业词汇的网络搜索中位数最高,其次是 AD(n = 8)和 AE(n = 2,图 1)。分析表明,欧洲各国的共同搜索主题包括一般疾病信息、年龄组、本地化和治疗,各国之间略有不同(图 2A)。非专业术语的关键词通常与其他疾病有关。根据搜索词的不同,某些类别的网络查询侧重于不同的子类别(图 2B)。例如,在使用非专业用语时,更多的国家搜索(自然)疗法和肛门定位,只有与注意力缺失症有关的搜索包括对动物的搜索。不过,搜索词之间也有相似之处,脸部、手部和头皮是最常被搜索的局部。与年龄相关的网络搜索主要涉及婴儿和儿童,而在奥地利和德国,成年人是唯一的搜索对象。与之前的研究一致,一项综述研究和一项全球众包方法都发现,AD 一词的使用频率高于 AE。3, 4 然而,特定国家的非专业用语的网络搜索次数几乎是 AE 的两倍,并且在大多数国家都受到青睐,这表明普通人群可能对有关 AD 或 AE 的学术争论并不感兴趣,而是在寻求与疾病相关的一般信息,因为诊断结果可能尚未可知。例如,常用的非专业用语 "湿疹 "缺乏准确性,可能包括其他皮肤病,如脂溢性湿疹或麻疹湿疹,这些疾病都会出现湿疹性皮损。2, 3 此外,欧洲不同国家的搜索主题和数量各不相同,这可能反映了各国人口对 AD 的特定需求,在传播可靠准确的在线健康信息时应加以考虑。此外,AD、AE 及其非专业用语之间在内容上的差异可能表明人们对不同疾病的混淆和认知,这一点应在患者交流中加以解决。3 该研究强调了欧洲人在网上搜索疾病相关信息时对 AD 和 AE 非专业用语的偏好。这些发现提倡在健康信息和患者交流中使用标准化的术语和语言,并根据各国的具体需求对信息进行调整。汉娜-韦克进行了统计分析。Sebastian Sitaru、Emma K. Johansson、Jesper Elberling、Anaïs Doll、Electra Nicolaidou、Emanuele Scala、Michael J. Boffa、Lea Schmidt、Mariusz Sikora、Tiago Torres 和 Pavel V. Chernyshov 提供了数据,并对结果讨论和最终手稿的起草做出了积极贡献。Hannah Wecker、Stefanie Ziehfreund、Sebastian Sitaru、Anaïs Doll、Electra Nicolaidou、Emanuele Scala、Michael J. Boffa、Lea Schmidt、Mariusz Sikora 和 Pavel V. Chernyshov 没有需要声明的利益冲突。Emma K. Johansson 曾接受过 AbbVie、ACO、Almirall、LEO Pharma、Novartis、Pfizer、Sanofi-Genzyme 以及瑞典哮喘和过敏协会的演讲酬金和/或担任其顾问。Jesper Elberling 曾担任以下公司的顾问委员会成员,并/或从这些公司获得演讲酬金和/或会议和差旅费资助:辉瑞(Pfizer)、赛诺菲(Sanofi)、利奥制药(Leo Pharma)、诺华(Novartis)、阿斯利康(AstraZeneca)、Almirall、艾伯维(AbbVie)、礼来(Eli Lilly)、Galderma、武田(Takeda)、CSL Vifor。Tiago Torres 曾因在艾伯维、Almirall、安进、Arena Pharmaceuticals、Biocad、勃林格殷格翰、百时美施贵宝、Celgene、礼来、杨森、利奥制药、MSD、诺华、辉瑞、三星生物、山德士和赛诺菲赞助的活动中担任顾问和/或演讲人而获得酬金。亚历山大-辛克曾担任以下公司的顾问和/或领取演讲酬金和/或接受以下公司的资助和/或参与以下公司的临床试验:AbbVie, ALK Abello, Almirall, Amgen, Beiersdorf Dermo Medical, Bencard Allergie, BMS, Celgene, Eli Lilly, GSK, Incyte, Janssen Cilag, Leo Pharma, Miltenyi Biotec, MSD, Novartis, Pfizer, Sanofi-Aventis, Takeda Pharma, Thermo Fisher Scientific Phadia, UCB.慕尼黑工业大学
{"title":"Dilemmas of nomenclature: Web search analysis reveals European preferences in atopic skin diseases","authors":"Hannah Wecker,&nbsp;Stefanie Ziehfreund,&nbsp;Sebastian Sitaru,&nbsp;Emma K. Johansson,&nbsp;Jesper Elberling,&nbsp;Anaïs Doll,&nbsp;Electra Nicolaidou,&nbsp;Emanuele Scala,&nbsp;Michael J. Boffa,&nbsp;Lea Schmidt,&nbsp;Mariusz Sikora,&nbsp;Tiago Torres,&nbsp;Pavel V. Chernyshov,&nbsp;Alexander Zink","doi":"10.1002/clt2.12355","DOIUrl":"https://doi.org/10.1002/clt2.12355","url":null,"abstract":"&lt;p&gt;Atopic dermatitis (AD) or atopic eczema (AE) is a complex chronic inflammatory skin disease with a high prevalence and disease burden.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The nomenclature for this condition has long been the subject of controversial debate within the medical community and even among global experts.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; However, the terminology used not only affects experts, daily clinical practice, and research but especially patients and the general public in terms of their understanding and access to disease-related information.&lt;span&gt;&lt;sup&gt;2-5&lt;/sup&gt;&lt;/span&gt; Given the potential of crowdsourced internet data,&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; this study aimed to investigate the use of ‘atopic dermatitis’, ‘atopic eczema’, and their lay terms in internet searches and the content of these searches across 21 European countries in their respective main language.&lt;/p&gt;&lt;p&gt;A total of 71,620,240 AD-related searches, 33,913,480 AE-related searches, and 136,405,350 searches to the respective lay terms were identified across European countries between 02/2019 and 01/2023 using Google Ads Keyword Planner. The top 20 keywords for each country and search term were translated into English and inductively classified into 9 categories: &lt;i&gt;age group&lt;/i&gt;, &lt;i&gt;causes&lt;/i&gt;, &lt;i&gt;comorbidities&lt;/i&gt;, &lt;i&gt;general&lt;/i&gt; information, &lt;i&gt;localisation&lt;/i&gt;, &lt;i&gt;other disease&lt;/i&gt;, &lt;i&gt;others&lt;/i&gt;, &lt;i&gt;symptoms&lt;/i&gt;, and &lt;i&gt;treatment&lt;/i&gt;. Subcategories were formed for recurring keywords, for example, different body localisations. For cross-country comparison, the monthly number of web searches per 100,000 inhabitants was calculated. For detailed methodology, see the Appendix.&lt;/p&gt;&lt;p&gt;Most European countries (&lt;i&gt;n&lt;/i&gt; = 11) had the highest median number of web searches per 100,000 inhabitants for AD-related lay terms, followed by AD (&lt;i&gt;n&lt;/i&gt; = 8) and AE (&lt;i&gt;n&lt;/i&gt; = 2, Figure 1). Analysis revealed common search themes across European countries, including &lt;i&gt;general&lt;/i&gt; disease information, &lt;i&gt;age groups&lt;/i&gt;, &lt;i&gt;localisations&lt;/i&gt;, and &lt;i&gt;treatment&lt;/i&gt;, with slight variations between countries (Figure 2A). The lay term's keywords were often about other diseases. Depending on the search terms, internet queries in some categories focused on different subcategories (Figure 2B). For example, when using the lay term, more countries searched for &lt;i&gt;(natural) remedies&lt;/i&gt; and anogenital localisations, and only AD-related searches included searches for &lt;i&gt;animals&lt;/i&gt;. However, there were also similarities between the search terms, with &lt;i&gt;face&lt;/i&gt;, &lt;i&gt;hands&lt;/i&gt;, and &lt;i&gt;scalp&lt;/i&gt; being the most frequently searched localisations. &lt;i&gt;Age-&lt;/i&gt;related internet searches concerned primarily babies and children, whereas in Austria and Germany, adults were the only search subjects. Search content for lay terms appeared less differentiated than for the other search terms.&lt;/p&gt;&lt;p&gt;Consistent with previous research, both a review study and a global crowdsourced approach found that the term AD was used more freque","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12355","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140550044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to HLA-A*24:02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in HLA-B*58:01 carriers in Korean population; A multicenter cross-sectional case-control study 在韩国人群中,HLA-B*58:01 携带者的 HLA-A*24:02 更正会增加别嘌醇诱发的伴有嗜酸性粒细胞增多和全身症状的药物反应(DRESS)的风险;一项多中心横断面病例对照研究
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2024-04-05 DOI: 10.1002/clt2.12351

M. Y. Kim, J. Yun, D. Y. Kang, T. H. Kim, M. K. Oh, S. Lee, et al. HLA-A* 24: 02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms in HLA-B* 58: 01 carriers in a Korean population; a multicenter cross-sectional case-control study. Clin Transl Allergy. 2022 Sep 15;12(9):e12193.

This article [1] was published with a technical error in Figure 2, a size of bars in the allopurinol-tolerant controls. The authors have re-examined the data and confirmed that this correction would not have resulted in any alteration to the results or conclusion of the paper. The figure 2 should be shown as below.

M.M. Y. Kim、J. Yun、D. Y. Kang、T. H. Kim、M. K. Oh、S. Lee, et al. HLA-A* 24: 02 会增加韩国人群中 HLA-B* 58: 01 携带者发生别嘌醇诱导的伴有嗜酸性粒细胞增多和全身症状的药物反应的风险;一项多中心横断面病例对照研究。Clin Transl Allergy.2022 Sep 15;12(9):e12193.This article [1] was published with a technical error in Figure 2, a size of bars in the allopurinol-tolerant controls.作者重新检查了数据,确认这一改正不会对论文的结果或结论造成任何改变。图 2 应如下所示。
{"title":"Correction to HLA-A*24:02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in HLA-B*58:01 carriers in Korean population; A multicenter cross-sectional case-control study","authors":"","doi":"10.1002/clt2.12351","DOIUrl":"https://doi.org/10.1002/clt2.12351","url":null,"abstract":"<p>M. Y. Kim, J. Yun, D. Y. Kang, T. H. Kim, M. K. Oh, S. Lee, et al. HLA-A* 24: 02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms in HLA-B* 58: 01 carriers in a Korean population; a multicenter cross-sectional case-control study. Clin Transl Allergy. 2022 Sep 15;12(9):e12193.</p><p>This article [1] was published with a technical error in Figure 2, a size of bars in the allopurinol-tolerant controls. The authors have re-examined the data and confirmed that this correction would not have resulted in any alteration to the results or conclusion of the paper. The figure 2 should be shown as below.</p><p></p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12351","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140351695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of potential drug targets for allergic diseases from a genetic perspective: A mendelian randomization study 从基因角度识别过敏性疾病的潜在药物靶点:孟德尔随机化研究
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2024-04-04 DOI: 10.1002/clt2.12350
Hui Wang, Jianyu Pang, Yuguan Zhou, Qi Qi, Yuheng Tang, Samina Gul, Miaomiao Sheng, Juhua Dan, Wenru Tang
<div> <section> <h3> Background</h3> <p>Allergic diseases typically refer to a heterogeneous group of conditions primarily caused by the activation of mast cells or eosinophils, including atopic dermatitis (AD), allergic rhinitis (AR), and asthma. Asthma, AR, and AD collectively affect approximately one-fifth of the global population, imposing a significant economic burden on society. Despite the availability of drugs to treat allergic diseases, they have been shown to be insufficient in controlling relapses and halting disease progression. Therefore, new drug targets are needed to prevent the onset of allergic diseases.</p> </section> <section> <h3> Method</h3> <p>We employed a Mendelian randomization approach to identify potential drug targets for the treatment of allergic diseases. Leveraging 1798 genetic instruments for 1537 plasma proteins from the latest reported Genome-Wide Association Studies (GWAS), we analyzed the GWAS summary statistics of Ferreira MA et al. (nCase = 180,129, nControl = 180,709) using the Mendelian randomization method. Furthermore, we validated our findings in the GWAS data from the FinnGen and UK Biobank cohorts. Subsequently, we conducted sensitivity tests through reverse causal analysis, Bayesian colocalization analysis, and phenotype scanning. Additionally, we performed protein-protein interaction analysis to determine the interaction between causal proteins. Finally, based on the potential protein targets, we conducted molecular docking to identify potential drugs for the treatment of allergic diseases.</p> </section> <section> <h3> Results</h3> <p>At Bonferroni significance (<i>p</i> < 3.25 × 10<sup>−5</sup>), the Mendelian randomization analysis revealed 11 significantly associated protein-allergic disease pairs. Among these, the increased levels of TNFAIP3, ERBB3, TLR1, and IL1RL2 proteins were associated with a reduced risk of allergic diseases, with corresponding odds ratios of 0.82 (0.76–0.88), 0.74 (0.66–0.82), 0.49 (0.45–0.55), and 0.81 (0.75–0.87), respectively. Conversely, increased levels of IL6R, IL1R1, ITPKA, IL1RL1, KYNU, LAYN, and LRP11 proteins were linked to an elevated risk of allergic diseases, with corresponding odds ratios of 1.04 (1.03–1.05), 1.25 (1.18–1.34), 1.48 (1.25–1.75), 1.14 (1.11–1.18), 1.09 (1.05–1.12), 1.96 (1.56–2.47), and 1.05 (1.03–1.07), respectively. Bayesian colocalization analysis suggested that LAYN (coloc.abf-PPH4 = 0.819) and TNFAIP3 (coloc.abf-PPH4 = 0.930) share the same variant associated with allergic diseases.</p> </section> <section> <h3> Conclusions</h3> <p>Our s
背景过敏性疾病通常是指一组主要由肥大细胞或嗜酸性粒细胞活化引起的异质性疾病,包括特应性皮炎(AD)、过敏性鼻炎(AR)和哮喘。哮喘、过敏性鼻炎和过敏性皮炎共影响着全球约五分之一的人口,给社会造成了巨大的经济负担。尽管目前已有治疗过敏性疾病的药物,但已证明这些药物不足以控制复发和阻止疾病进展。因此,需要新的药物靶点来预防过敏性疾病的发生。 方法 我们采用孟德尔随机化方法来确定治疗过敏性疾病的潜在药物靶点。利用最新报道的全基因组关联研究(GWAS)中 1537 种血浆蛋白的 1798 个遗传工具,我们使用孟德尔随机方法分析了 Ferreira MA 等人的 GWAS 统计摘要(nCase = 180,129, nControl = 180,709)。此外,我们还通过 FinnGen 和英国生物库队列的 GWAS 数据验证了我们的研究结果。随后,我们通过反向因果分析、贝叶斯共定位分析和表型扫描进行了敏感性测试。此外,我们还进行了蛋白-蛋白相互作用分析,以确定因果蛋白之间的相互作用。最后,根据潜在的蛋白质靶点,我们进行了分子对接,以确定治疗过敏性疾病的潜在药物。 结果 在Bonferroni显著性(p < 3.25 × 10-5)下,孟德尔随机分析发现了11对显著相关的蛋白质-过敏性疾病。其中,TNFAIP3、ERBB3、TLR1 和 IL1RL2 蛋白水平的升高与过敏性疾病风险的降低有关,相应的几率比分别为 0.82(0.76-0.88)、0.74(0.66-0.82)、0.49(0.45-0.55)和 0.81(0.75-0.87)。相反,IL6R、IL1R1、ITPKA、IL1RL1、KYNU、LAYN 和 LRP11 蛋白水平的升高与过敏性疾病风险的升高有关,相应的几率比为 1.相应的几率比分别为 1.04 (1.03-1.05)、1.25 (1.18-1.34)、1.48 (1.25-1.75)、1.14 (1.11-1.18)、1.09 (1.05-1.12)、1.96 (1.56-2.47) 和 1.05 (1.03-1.07)。贝叶斯共定位分析表明,LAYN(coloc.abf-PPH4 = 0.819)和 TNFAIP3(coloc.abf-PPH4 = 0.930)具有与过敏性疾病相关的相同变异。 结论 我们的研究表明 TNFAIP3 和 LAYN 的表达水平与过敏性疾病风险之间存在因果关系,这表明它们是治疗这些疾病的潜在药物靶点,值得进一步临床研究。
{"title":"Identification of potential drug targets for allergic diseases from a genetic perspective: A mendelian randomization study","authors":"Hui Wang,&nbsp;Jianyu Pang,&nbsp;Yuguan Zhou,&nbsp;Qi Qi,&nbsp;Yuheng Tang,&nbsp;Samina Gul,&nbsp;Miaomiao Sheng,&nbsp;Juhua Dan,&nbsp;Wenru Tang","doi":"10.1002/clt2.12350","DOIUrl":"https://doi.org/10.1002/clt2.12350","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Allergic diseases typically refer to a heterogeneous group of conditions primarily caused by the activation of mast cells or eosinophils, including atopic dermatitis (AD), allergic rhinitis (AR), and asthma. Asthma, AR, and AD collectively affect approximately one-fifth of the global population, imposing a significant economic burden on society. Despite the availability of drugs to treat allergic diseases, they have been shown to be insufficient in controlling relapses and halting disease progression. Therefore, new drug targets are needed to prevent the onset of allergic diseases.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We employed a Mendelian randomization approach to identify potential drug targets for the treatment of allergic diseases. Leveraging 1798 genetic instruments for 1537 plasma proteins from the latest reported Genome-Wide Association Studies (GWAS), we analyzed the GWAS summary statistics of Ferreira MA et al. (nCase = 180,129, nControl = 180,709) using the Mendelian randomization method. Furthermore, we validated our findings in the GWAS data from the FinnGen and UK Biobank cohorts. Subsequently, we conducted sensitivity tests through reverse causal analysis, Bayesian colocalization analysis, and phenotype scanning. Additionally, we performed protein-protein interaction analysis to determine the interaction between causal proteins. Finally, based on the potential protein targets, we conducted molecular docking to identify potential drugs for the treatment of allergic diseases.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;At Bonferroni significance (&lt;i&gt;p&lt;/i&gt; &lt; 3.25 × 10&lt;sup&gt;−5&lt;/sup&gt;), the Mendelian randomization analysis revealed 11 significantly associated protein-allergic disease pairs. Among these, the increased levels of TNFAIP3, ERBB3, TLR1, and IL1RL2 proteins were associated with a reduced risk of allergic diseases, with corresponding odds ratios of 0.82 (0.76–0.88), 0.74 (0.66–0.82), 0.49 (0.45–0.55), and 0.81 (0.75–0.87), respectively. Conversely, increased levels of IL6R, IL1R1, ITPKA, IL1RL1, KYNU, LAYN, and LRP11 proteins were linked to an elevated risk of allergic diseases, with corresponding odds ratios of 1.04 (1.03–1.05), 1.25 (1.18–1.34), 1.48 (1.25–1.75), 1.14 (1.11–1.18), 1.09 (1.05–1.12), 1.96 (1.56–2.47), and 1.05 (1.03–1.07), respectively. Bayesian colocalization analysis suggested that LAYN (coloc.abf-PPH4 = 0.819) and TNFAIP3 (coloc.abf-PPH4 = 0.930) share the same variant associated with allergic diseases.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Our s","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12350","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140348563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world drug use in asthma, chronic obstructive pulmonary disease, rhinitis, cough, and cold in Finland from 1990 to 2021: Association with reduced disease burden 1990 至 2021 年芬兰哮喘、慢性阻塞性肺病、鼻炎、咳嗽和感冒的实际用药情况:与疾病负担减轻的关系。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2024-04-01 DOI: 10.1002/clt2.12340
Tiina Mattila, Vesa Jormanainen, Marina Erhola, Tuula Vasankari, Sanna Toppila-Salmi, Fredrik Herse, Riikka-Leena Leskelä, Tari Haahtela
<p>Asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis are major long-term airway diseases.<span><sup>1-5</sup></span> Asthma appears in all age groups and COPD causes major morbidity and mortality particularly in smokers.<span><sup>1, 2, 5</sup></span> Allergic rhinitis and other allergic conditions are often associated with asthma.<span><sup>3, 4, 6</sup></span></p><p>In Finland, three nationwide respiratory programmes have been implemented since 1994: the Asthma Programme (1994–2004), the COPD Programme (1998–2007), and the Allergy Programme (2008–2018).<span><sup>4, 6</sup></span> After the 1990s, the burden of asthma, COPD, and allergic conditions has decreased and the prevalence has stabilised.<span><sup>4, 6</sup></span> Smoking has also decreased.<span><sup>7</sup></span></p><p>International guidelines are available for asthma (since 1995), COPD (since 1997), and chronic rhinitis (since 2005).<span><sup>1-3</sup></span></p><p>Inhaled short- and long-acting β2 adrenoceptor agonists (LABA), muscarinic receptor antagonists (LAMA), and corticosteroids (ICS) have been used for first-line treatment in asthma and COPD since the 1990s.<span><sup>1, 2, 4, 8</sup></span> Intranasal corticosteroids have been used in rhinitis for decades.<span><sup>3</sup></span></p><p>In the present study, we present consumption (sales) data of medication for asthma, COPD, rhinitis, cough, and cold from 1990 to 2021, and analyse the overall costs of asthma and severe COPD from 1996 to 2018.</p><p>Since 1988, the <i>Social Insurance Institution of Finland</i> (SII) and the <i>Finnish Medicines Agency</i> (Fimea) have jointly published the <i>Finnish Statistics on Medicine</i> (FSM), which includes all medications purchased in Finland.<span><sup>8</sup></span></p><p>For sales statistics, medications are listed according to the <i>Anatomical Therapeutic Chemical</i> groups (R, Respiratory system).<span><sup>9</sup></span> We report medication consumption for asthma and COPD (R03; inhaled (R03A-B), systemic (R03DC), and molecular targeted medications (R03DX05, R03DX08–10)), nasal preparations (R01), systemic antihistamines (R06), and medications for cough and cold (R05; such as expectorants (R05C) and cough suppressants (R05D)).<span><sup>9</sup></span></p><p>Medication consumption was followed using the unit <i>Defined Daily Doses</i> (DDD/1000 population/day) in the Finnish nationwide registries (FSM, SII). The results are presented as annual time series.</p><p>Cost analysis was made for asthma and severe COPD comparably to our previous work (data 1996–2018).<span><sup>4</sup></span> This included only those individuals entitled to special reimbursed medication (same criterions 1996–2018).<span><sup>4</sup></span></p><p>The population of Finland was accessed from <i>Statistics Finland,</i> and it increased from 5.0 million in 1990 to 5.5 million in 2021 (+10%).</p><p>Respiratory medications consumption increased from 98 in 1996 to 200 DDD/1000/
4 然而,阻塞性气道疾病造成的总体负担和成本却有所下降(图2)。大部分节省的费用最好归功于哮喘诊断和早期抗炎(ICS)治疗的改善,以及国家哮喘计划(1994-2004年)。这一趋势在 "过敏计划"(2008-2018 年)期间趋于稳定。直到最近几年,生物制剂的使用一直处于边缘化状态,其成本也未包括在本计算中。与吸入药物相比,生物制剂价格昂贵,但在严重哮喘中使用生物制剂是有针对性的。10 在芬兰使用生物制剂的成本效益证据应单独评估。如果咳嗽的根本原因是哮喘或慢性阻塞性肺病,则应立即对症下药。1, 2 虽然缺乏效益证据(13),但止咳药的市场经济意义重大。总之,针对哮喘、慢性阻塞性肺病和过敏性疾病的系统性、全国性公共卫生干预措施,改善了芬兰对这些疾病的诊断、早期治疗和认识。因此,呼吸系统疾病的用药量显著增加,但患者和社会的总体负担却有所减轻。重要的是,治疗咳嗽和感冒的对症药物减少了。Vesa Jormanainen、Fredrik Herse、Riikka-Leena Leskelä 和 Tiina Mattila 收集并分析了大部分数据。Tiina Mattila 和 Tari Haahtela 对手稿的第一版进行了概述。芬兰卫生与福利研究所、赫尔辛基和乌西马院区(HUH)以及肺部疾病研究基金会为数据收集和分析以及论文撰写提供了资助。
{"title":"Real-world drug use in asthma, chronic obstructive pulmonary disease, rhinitis, cough, and cold in Finland from 1990 to 2021: Association with reduced disease burden","authors":"Tiina Mattila,&nbsp;Vesa Jormanainen,&nbsp;Marina Erhola,&nbsp;Tuula Vasankari,&nbsp;Sanna Toppila-Salmi,&nbsp;Fredrik Herse,&nbsp;Riikka-Leena Leskelä,&nbsp;Tari Haahtela","doi":"10.1002/clt2.12340","DOIUrl":"10.1002/clt2.12340","url":null,"abstract":"&lt;p&gt;Asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis are major long-term airway diseases.&lt;span&gt;&lt;sup&gt;1-5&lt;/sup&gt;&lt;/span&gt; Asthma appears in all age groups and COPD causes major morbidity and mortality particularly in smokers.&lt;span&gt;&lt;sup&gt;1, 2, 5&lt;/sup&gt;&lt;/span&gt; Allergic rhinitis and other allergic conditions are often associated with asthma.&lt;span&gt;&lt;sup&gt;3, 4, 6&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In Finland, three nationwide respiratory programmes have been implemented since 1994: the Asthma Programme (1994–2004), the COPD Programme (1998–2007), and the Allergy Programme (2008–2018).&lt;span&gt;&lt;sup&gt;4, 6&lt;/sup&gt;&lt;/span&gt; After the 1990s, the burden of asthma, COPD, and allergic conditions has decreased and the prevalence has stabilised.&lt;span&gt;&lt;sup&gt;4, 6&lt;/sup&gt;&lt;/span&gt; Smoking has also decreased.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;International guidelines are available for asthma (since 1995), COPD (since 1997), and chronic rhinitis (since 2005).&lt;span&gt;&lt;sup&gt;1-3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Inhaled short- and long-acting β2 adrenoceptor agonists (LABA), muscarinic receptor antagonists (LAMA), and corticosteroids (ICS) have been used for first-line treatment in asthma and COPD since the 1990s.&lt;span&gt;&lt;sup&gt;1, 2, 4, 8&lt;/sup&gt;&lt;/span&gt; Intranasal corticosteroids have been used in rhinitis for decades.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In the present study, we present consumption (sales) data of medication for asthma, COPD, rhinitis, cough, and cold from 1990 to 2021, and analyse the overall costs of asthma and severe COPD from 1996 to 2018.&lt;/p&gt;&lt;p&gt;Since 1988, the &lt;i&gt;Social Insurance Institution of Finland&lt;/i&gt; (SII) and the &lt;i&gt;Finnish Medicines Agency&lt;/i&gt; (Fimea) have jointly published the &lt;i&gt;Finnish Statistics on Medicine&lt;/i&gt; (FSM), which includes all medications purchased in Finland.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;For sales statistics, medications are listed according to the &lt;i&gt;Anatomical Therapeutic Chemical&lt;/i&gt; groups (R, Respiratory system).&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; We report medication consumption for asthma and COPD (R03; inhaled (R03A-B), systemic (R03DC), and molecular targeted medications (R03DX05, R03DX08–10)), nasal preparations (R01), systemic antihistamines (R06), and medications for cough and cold (R05; such as expectorants (R05C) and cough suppressants (R05D)).&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Medication consumption was followed using the unit &lt;i&gt;Defined Daily Doses&lt;/i&gt; (DDD/1000 population/day) in the Finnish nationwide registries (FSM, SII). The results are presented as annual time series.&lt;/p&gt;&lt;p&gt;Cost analysis was made for asthma and severe COPD comparably to our previous work (data 1996–2018).&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; This included only those individuals entitled to special reimbursed medication (same criterions 1996–2018).&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The population of Finland was accessed from &lt;i&gt;Statistics Finland,&lt;/i&gt; and it increased from 5.0 million in 1990 to 5.5 million in 2021 (+10%).&lt;/p&gt;&lt;p&gt;Respiratory medications consumption increased from 98 in 1996 to 200 DDD/1000/","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12340","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140334923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regional, sex, and age inequities in asthma hospital admissions in Spain and Portugal 西班牙和葡萄牙哮喘病住院患者在地区、性别和年龄方面的不平等。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2024-03-30 DOI: 10.1002/clt2.12349
Rafael José Vieira, Ana Margarida Pereira, Luís Taborda-Barata, Frederico S. Regateiro, Manuel Marques-Cruz, Carlos Robalo Cordeiro, Cláudia Chaves Loureiro, Ignacio J. Dávila, Jean Bousquet, João A. Fonseca, Bernardo Sousa-Pinto

Background

Asthma presents a significant health challenge, imposing a considerable burden on healthcare services. Discrepancies in asthma-related hospitalisations may reflect underlying health disparities. We aimed to analyse inequities in asthma hospital admissions in mainland Portugal and Spain, from a regional perspective and considering sex and age.

Methods

We conducted a retrospective study using data from the Spanish and Portuguese national hospitalisations databases. We calculated crude national and regional yearly hospitalisation rates according per Nomenclature of Territorial Units for Statistics region. Additionally, we calculated hospitalisation rates adjusted for asthma prevalence and the female-to-male ratio in asthma hospital admissions per age group, considering the female-to-male ratio in the overall population.

Results

Between 2012 and 2016, there were 92,084 asthma hospital admissions in mainland Spain and 7717 in mainland Portugal. There was a trend for a higher-than-average rate of asthma-related hospitalisations in the Northern regions of both countries. Women had a hospitalisation rate that was 3.2 times higher than men. Age was associated with higher risk for asthma hospitalisation, with individuals aged 65 and older displaying a hospitalisation rate 4.5 times higher than those under 65. Additionally, while hospitalisations in women aged <65 years were 2.3 times more likely than in men of the same age, hospitalisations in women aged ≥65 years were 3.5 times higher than in men aged ≥65 years.

Conclusion

This study suggests that marked regional inequities in asthma hospital admissions exist in Spain and Portugal. Additionally, women are particularly at risk of hospitalisation due to asthma, and such risk increases with age.

背景:哮喘是一项重大的健康挑战,给医疗保健服务造成了相当大的负担。与哮喘相关的住院人数差异可能反映出潜在的健康差异。我们旨在从地区视角并考虑性别和年龄因素,分析葡萄牙和西班牙本土哮喘住院人数的不平等现象:我们利用西班牙和葡萄牙国家住院数据库中的数据进行了一项回顾性研究。我们根据地区统计单位命名法计算了全国和地区的粗略年度住院率。此外,我们还计算了根据哮喘发病率和各年龄组哮喘住院患者的男女比例调整后的住院率,并考虑了总人口中的男女比例:2012年至2016年期间,西班牙本土有92084例哮喘住院病例,葡萄牙本土有7717例。两国北部地区的哮喘相关住院率均高于平均水平。女性的住院率是男性的 3.2 倍。年龄与哮喘住院风险较高有关,65 岁及以上人群的住院率是 65 岁以下人群的 4.5 倍。此外,女性哮喘患者的住院率是男性的 3.2 倍:这项研究表明,西班牙和葡萄牙的哮喘住院率存在明显的地区不平等。此外,女性因哮喘住院的风险尤其高,而且这种风险随着年龄的增长而增加。
{"title":"Regional, sex, and age inequities in asthma hospital admissions in Spain and Portugal","authors":"Rafael José Vieira,&nbsp;Ana Margarida Pereira,&nbsp;Luís Taborda-Barata,&nbsp;Frederico S. Regateiro,&nbsp;Manuel Marques-Cruz,&nbsp;Carlos Robalo Cordeiro,&nbsp;Cláudia Chaves Loureiro,&nbsp;Ignacio J. Dávila,&nbsp;Jean Bousquet,&nbsp;João A. Fonseca,&nbsp;Bernardo Sousa-Pinto","doi":"10.1002/clt2.12349","DOIUrl":"10.1002/clt2.12349","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Asthma presents a significant health challenge, imposing a considerable burden on healthcare services. Discrepancies in asthma-related hospitalisations may reflect underlying health disparities. We aimed to analyse inequities in asthma hospital admissions in mainland Portugal and Spain, from a regional perspective and considering sex and age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective study using data from the Spanish and Portuguese national hospitalisations databases. We calculated crude national and regional yearly hospitalisation rates according per Nomenclature of Territorial Units for Statistics region. Additionally, we calculated hospitalisation rates adjusted for asthma prevalence and the female-to-male ratio in asthma hospital admissions per age group, considering the female-to-male ratio in the overall population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Between 2012 and 2016, there were 92,084 asthma hospital admissions in mainland Spain and 7717 in mainland Portugal. There was a trend for a higher-than-average rate of asthma-related hospitalisations in the Northern regions of both countries. Women had a hospitalisation rate that was 3.2 times higher than men. Age was associated with higher risk for asthma hospitalisation, with individuals aged 65 and older displaying a hospitalisation rate 4.5 times higher than those under 65. Additionally, while hospitalisations in women aged &lt;65 years were 2.3 times more likely than in men of the same age, hospitalisations in women aged ≥65 years were 3.5 times higher than in men aged ≥65 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study suggests that marked regional inequities in asthma hospital admissions exist in Spain and Portugal. Additionally, women are particularly at risk of hospitalisation due to asthma, and such risk increases with age.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12349","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140329726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ethnic differences in depression and anxiety among adults with atopic eczema: Population-based matched cohort studies within UK primary care 患有特应性湿疹的成年人在抑郁和焦虑方面的种族差异:英国初级保健中基于人群的匹配队列研究。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2024-03-25 DOI: 10.1002/clt2.12348
Elizabeth I. Adesanya, Alasdair Henderson, Joseph F. Hayes, Alexandra Lewin, Rohini Mathur, Amy Mulick, Caroline Morton, Catherine Smith, Sinéad M. Langan, Kathryn E. Mansfield

Background

Evidence demonstrates that individuals with atopic eczema (eczema) have increased depression and anxiety; however, the role of ethnicity in these associations is poorly understood. We aimed to investigate whether associations between eczema and depression or anxiety differed between adults from white and minority ethnic groups in the UK.

Methods

We used UK Clinical Practice Research Datalink GOLD to conduct matched cohort studies of adults (≥18 years) with ethnicity recorded in primary care electronic health records (April 2006-January 2020). We matched (age, sex, practice) adults with eczema to up to five adults without. We used stratified Cox regression with an interaction between eczema and ethnicity, to estimate hazard ratios (HRs) for associations between eczema and incident depression and anxiety in individuals from white ethnic groups and a pooled minority ethnic group (adults from Black, South Asian, Mixed and Other groups).

Results

We identified separate cohorts for depression (215,073 with eczema matched to 646,539 without) and anxiety (242,598 with eczema matched to 774,113 without). After adjusting for matching variables and potential confounders (age, sex, practice, deprivation, calendar period), we found strong evidence (p < 0.01) of ethnic differences in associations between eczema and depression (minority ethnic groups: HR = 1.33, 95% CI = 1.22,1.45; white ethnic groups: HR = 1.15, 95% CI = 1.12,1.17) and anxiety (minority ethnic groups: HR = 1.41, 95% CI = 1.28,1.55; white ethnic groups: HR = 1.17, 95% CI = 1.14,1.19).

Conclusions

Adults with eczema from minority ethnic groups appear to be at increased depression and anxiety risk compared with their white counterparts. Culturally adapted mental health promotion and prevention strategies should be considered in individuals with eczema from minority ethnic groups.

背景:有证据表明,特应性湿疹(湿疹)患者的抑郁和焦虑程度会增加;然而,人们对种族在这些关联中的作用却知之甚少。我们的目的是调查英国白人和少数民族成年人湿疹与抑郁或焦虑之间的关系是否存在差异:我们利用英国临床实践研究数据链 GOLD 对初级保健电子健康记录(2006 年 4 月至 2020 年 1 月)中有种族记录的成年人(≥18 岁)进行了匹配队列研究。我们将患有湿疹的成人与最多五名未患湿疹的成人进行了配对(年龄、性别、工作单位)。我们使用分层考克斯回归法(湿疹与种族之间存在交互作用)估算了白人种族群体和少数种族群体(黑人、南亚人、混血人和其他群体的成年人)中湿疹与抑郁和焦虑事件之间的危险比(HRs):我们确定了抑郁(215,073 人患有湿疹,646,539 人未患有湿疹)和焦虑(242,598 人患有湿疹,774,113 人未患有湿疹)的独立队列。在对配对变量和潜在混杂因素(年龄、性别、职业、贫困程度、日历期)进行调整后,我们发现了强有力的证据(p 结论:"我们的研究结果表明,患有湿疹的少数民族成年人中,有一半人患有抑郁症,有一半人患有焦虑症:与白人相比,少数民族群体中患有湿疹的成年人抑郁和焦虑的风险似乎更高。对于少数民族湿疹患者,应考虑采取适合其文化背景的心理健康促进和预防策略。
{"title":"Ethnic differences in depression and anxiety among adults with atopic eczema: Population-based matched cohort studies within UK primary care","authors":"Elizabeth I. Adesanya,&nbsp;Alasdair Henderson,&nbsp;Joseph F. Hayes,&nbsp;Alexandra Lewin,&nbsp;Rohini Mathur,&nbsp;Amy Mulick,&nbsp;Caroline Morton,&nbsp;Catherine Smith,&nbsp;Sinéad M. Langan,&nbsp;Kathryn E. Mansfield","doi":"10.1002/clt2.12348","DOIUrl":"10.1002/clt2.12348","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Evidence demonstrates that individuals with atopic eczema (eczema) have increased depression and anxiety; however, the role of ethnicity in these associations is poorly understood. We aimed to investigate whether associations between eczema and depression or anxiety differed between adults from white and minority ethnic groups in the UK.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used UK Clinical Practice Research Datalink GOLD to conduct matched cohort studies of adults (≥18 years) with ethnicity recorded in primary care electronic health records (April 2006-January 2020). We matched (age, sex, practice) adults with eczema to up to five adults without. We used stratified Cox regression with an interaction between eczema and ethnicity, to estimate hazard ratios (HRs) for associations between eczema and incident depression and anxiety in individuals from white ethnic groups and a pooled minority ethnic group (adults from Black, South Asian, Mixed and Other groups).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified separate cohorts for depression (215,073 with eczema matched to 646,539 without) and anxiety (242,598 with eczema matched to 774,113 without). After adjusting for matching variables and potential confounders (age, sex, practice, deprivation, calendar period), we found strong evidence (<i>p</i> &lt; 0.01) of ethnic differences in associations between eczema and depression (minority ethnic groups: HR = 1.33, 95% CI = 1.22,1.45; white ethnic groups: HR = 1.15, 95% CI = 1.12,1.17) and anxiety (minority ethnic groups: HR = 1.41, 95% CI = 1.28,1.55; white ethnic groups: HR = 1.17, 95% CI = 1.14,1.19).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Adults with eczema from minority ethnic groups appear to be at increased depression and anxiety risk compared with their white counterparts. Culturally adapted mental health promotion and prevention strategies should be considered in individuals with eczema from minority ethnic groups.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 3","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12348","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A survey study on antibiotic prescription practices for acute asthma exacerbations: An European academy of allergy and clinical immunology task force report 关于哮喘急性加重期抗生素处方做法的调查研究:欧洲过敏与临床免疫学学会特别工作组报告。
IF 4.4 2区 医学 Q2 ALLERGY Pub Date : 2024-03-18 DOI: 10.1002/clt2.12345
Anne-Lotte Redel, Wojciech Feleszko, Alessandra Arcolaci, Francesca Cefaloni, Marina Atanaskovic-Markovic, Gert-Jan Braunstahl, Cristina Boccabella, Matteo Bonini, Aspasia Karavelia, Eefje Louwers, Norbert Mülleneisen, Liam O'Mahony, Laura Pini, Anna Rapiejko, Esmeralda Shehu, Milena Sokolowska, Eva Untersmayr, Gerdien Tramper-Stranders, EAACI Task Force on Conscious and Rational use of Antibiotics in Allergic Diseases

Introduction

Guidelines recommend treating asthma exacerbations (AAEs) with bronchodilators combined with inhaled and/or systemic corticosteroids. Indications for antibiotic prescriptions for AAEs are usually not incorporated although the literature shows antibiotics are frequently prescribed.

Aim

To investigate the antibiotic prescription rates in AAEs and explore the possible determining factors of those practices.

Methods

A digital survey was created to determine the antibiotic prescription rates in AAEs and the influencing factors for the prescription practices. The survey was distributed among European academy of allergy and clinical immunology (EAACI) members by mass emailing and through regional/national societies in the Netherlands, Italy, Greece, and Poland. Furthermore, we retrieved local antibiotic prescription rates.

Results

In total, 252 participants completed the survey. Respondents stated that there is a lack of guidelines to prescribe antibiotics in AAEs. The median antibiotic prescription rate in this study was 19% [IQR: 0%–40%] and was significantly different between 4 professions: paediatrics 0% [IQR: 0%–37%], pulmonologists 25% [IQR: 10%–50%], general practitioners 25% [IQR: 0%–50%], and allergologists 17% [IQR: 0%–33%]) (p = 0.046). Additional diagnostic tests were performed in 71.4% of patients before prescription and the most common antibiotic classes prescribed were macrolides (46.0%) and penicillin (42.9%). Important clinical factors for health care providers to prescribe antibiotics were colorised/purulent sputum, abnormal lung sounds during auscultation, fever, and presence of comorbidities.

Conclusion

In 19% of patients with AAEs, antibiotics were prescribed in various classes with a broad range among different subspecialities. This study stresses the urgency to compose evidence-based guidelines to aim for more rational antibiotic prescriptions for AAE.

导言:指南建议使用支气管扩张剂联合吸入和/或全身皮质类固醇治疗哮喘加重(AAE)。目的:调查AAE中的抗生素处方率,并探索这些做法的可能决定因素:方法:为确定AAE中的抗生素处方率以及处方做法的影响因素,制作了一份数字调查表。我们通过群发邮件以及荷兰、意大利、希腊和波兰的地区/国家协会向欧洲过敏与临床免疫学学会(EAACI)会员发放了调查问卷。此外,我们还检索了当地的抗生素处方率:共有 252 位参与者完成了调查。受访者表示,AAE 缺乏抗生素处方指南。本研究的抗生素处方率中位数为 19% [IQR:0%-40%],4 个专业之间存在显著差异:儿科医生 0% [IQR:0%-37%],肺科医生 25% [IQR:10%-50%],全科医生 25% [IQR:0%-50%],过敏科医生 17% [IQR:0%-33%])(p = 0.046)。71.4%的患者在处方前进行了额外的诊断测试,处方中最常见的抗生素类别是大环内酯类(46.0%)和青霉素类(42.9%)。医护人员开具抗生素处方的重要临床因素是痰液变色/化脓、听诊时肺部听诊异常、发热和存在合并症:在 19% 的 AAE 患者中,不同亚专科处方的抗生素种类繁多。本研究强调了制定循证指南的紧迫性,旨在为AAE患者开出更合理的抗生素处方。
{"title":"A survey study on antibiotic prescription practices for acute asthma exacerbations: An European academy of allergy and clinical immunology task force report","authors":"Anne-Lotte Redel,&nbsp;Wojciech Feleszko,&nbsp;Alessandra Arcolaci,&nbsp;Francesca Cefaloni,&nbsp;Marina Atanaskovic-Markovic,&nbsp;Gert-Jan Braunstahl,&nbsp;Cristina Boccabella,&nbsp;Matteo Bonini,&nbsp;Aspasia Karavelia,&nbsp;Eefje Louwers,&nbsp;Norbert Mülleneisen,&nbsp;Liam O'Mahony,&nbsp;Laura Pini,&nbsp;Anna Rapiejko,&nbsp;Esmeralda Shehu,&nbsp;Milena Sokolowska,&nbsp;Eva Untersmayr,&nbsp;Gerdien Tramper-Stranders,&nbsp;EAACI Task Force on Conscious and Rational use of Antibiotics in Allergic Diseases","doi":"10.1002/clt2.12345","DOIUrl":"10.1002/clt2.12345","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Guidelines recommend treating asthma exacerbations (AAEs) with bronchodilators combined with inhaled and/or systemic corticosteroids. Indications for antibiotic prescriptions for AAEs are usually not incorporated although the literature shows antibiotics are frequently prescribed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To investigate the antibiotic prescription rates in AAEs and explore the possible determining factors of those practices.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A digital survey was created to determine the antibiotic prescription rates in AAEs and the influencing factors for the prescription practices. The survey was distributed among European academy of allergy and clinical immunology (EAACI) members by mass emailing and through regional/national societies in the Netherlands, Italy, Greece, and Poland. Furthermore, we retrieved local antibiotic prescription rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 252 participants completed the survey. Respondents stated that there is a lack of guidelines to prescribe antibiotics in AAEs. The median antibiotic prescription rate in this study was 19% [IQR: 0%–40%] and was significantly different between 4 professions: paediatrics 0% [IQR: 0%–37%], pulmonologists 25% [IQR: 10%–50%], general practitioners 25% [IQR: 0%–50%], and allergologists 17% [IQR: 0%–33%]) (<i>p</i> = 0.046). Additional diagnostic tests were performed in 71.4% of patients before prescription and the most common antibiotic classes prescribed were macrolides (46.0%) and penicillin (42.9%). Important clinical factors for health care providers to prescribe antibiotics were colorised/purulent sputum, abnormal lung sounds during auscultation, fever, and presence of comorbidities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In 19% of patients with AAEs, antibiotics were prescribed in various classes with a broad range among different subspecialities. This study stresses the urgency to compose evidence-based guidelines to aim for more rational antibiotic prescriptions for AAE.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 3","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12345","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140142912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Translational Allergy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1